<?xml version="1.0" encoding="UTF-8"?><CAS version="2"><uima.cas.Sofa _indexed="0" _id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="P03296212A0603 The future of research with interferon may be divided into three areas: Efforts must be made to determine how best to translate the in vitro synergy into clinically meaningful terms; in order to exploit the fullest potential of IFN, research is moving toward using this agent earlier in disease either as an adjuvant after tumor debulking or after initial diagnosis; the medical community must rethink the natural history of some diseases, because the fullest potential of the biologic agents will most likely manifest itself when these agents are used together."/><uima.tcas.DocumentAnnotation _indexed="1" _id="8" _ref_sofa="1" begin="0" end="577" language="x-unspecified"/><edu.cmu.tanl.type.gene _indexed="1" _id="13" _ref_sofa="1" begin="23" end="32" Gene="interferon"/><edu.cmu.tanl.type.gene _indexed="1" _id="18" _ref_sofa="1" begin="190" end="192" Gene="IFN"/></CAS>